Metformax 1000

Metformin Hydrochloride, the active ingredient in Metformax 1000, is a biguanide presented as a 1000 mg oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control elevated blood glucose levels.

GNH USA supplies Metformax 1000 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The product meets EU Good Manufacturing Practice and undergoes strict, rigorous quality testing before release.

Metformax 1000 (metformin hydrochloride) is used in the management of glucose metabolism disorders, primarily type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycemic control and reduces fasting plasma glucose. - Prediabetes (impaired fasting glucose): delays progression to overt diabetes when combined with lifestyle measures. - Metabolic syndrome (as adjunct): assists in improving insulin sensitivity alongside diet and exercise.

Metformax 1000 may cause a range of adverse reactions, most of which are related to gastrointestinal tolerance and metabolic changes.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: loose stools that may be watery. - Metallic taste: transient alteration in taste perception. - Flatulence: increased intestinal gas. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: gradual decrease with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal accumulation of lactate, especially in renal impairment. - Severe hypoglycemia: when combined with insulin or sulfonylureas. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Skin reactions: rash, Stevens‑Johnson syndrome. - Pancreatitis: inflammation of the pancreas. - Anemia: due to reduced red blood cell production.

When prescribing Metformax 1000, clinicians should evaluate patient factors and monitor for safety concerns.

- Renal function assessment: check eGFR before initiation and periodically thereafter. - Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment. - Alcohol consumption: limit intake to reduce the risk of lactic acidosis. - Pregnancy and lactation: use only if potential benefits outweigh risks and after medical advice. - Monitoring: assess vitamin B12 levels periodically during long‑term therapy. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Metformax 1000 can interact with several medicines, affecting its plasma concentration or increasing the risk of adverse events.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure when combined. - Cimetidine: can increase metformin plasma levels, raising toxicity risk. - Nucleoside reverse transcriptase inhibitors (e.g., didanosine): heightened risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - Thiazide diuretics: can attenuate glucose‑lowering effect. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Corticosteroids: may increase blood glucose, requiring dose adjustment.